StockNews.com Upgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to “Buy”

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a buy rating in a research note published on Tuesday morning.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Stock Up 0.2 %

Shares of Oramed Pharmaceuticals stock opened at $2.37 on Tuesday. Oramed Pharmaceuticals has a 12-month low of $1.67 and a 12-month high of $3.67. The stock has a market capitalization of $96.42 million, a P/E ratio of 4.64 and a beta of 1.77. The company has a 50-day simple moving average of $2.40 and a 200 day simple moving average of $2.39.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.21. On average, equities analysts anticipate that Oramed Pharmaceuticals will post 0.24 earnings per share for the current year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ORMP. XTX Topco Ltd bought a new position in shares of Oramed Pharmaceuticals in the second quarter worth about $40,000. Virtu Financial LLC bought a new position in Oramed Pharmaceuticals in the 1st quarter worth approximately $68,000. Dimensional Fund Advisors LP lifted its holdings in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after buying an additional 10,774 shares in the last quarter. Renaissance Technologies LLC boosted its position in Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 108,700 shares during the last quarter. Finally, Murchinson Ltd. increased its stake in shares of Oramed Pharmaceuticals by 31.4% in the 1st quarter. Murchinson Ltd. now owns 1,379,495 shares of the biotechnology company’s stock valued at $4,028,000 after buying an additional 329,495 shares during the period. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.